IE43079B1 - Quinolone derivatives - Google Patents
Quinolone derivativesInfo
- Publication number
- IE43079B1 IE43079B1 IE352/76A IE35276A IE43079B1 IE 43079 B1 IE43079 B1 IE 43079B1 IE 352/76 A IE352/76 A IE 352/76A IE 35276 A IE35276 A IE 35276A IE 43079 B1 IE43079 B1 IE 43079B1
- Authority
- IE
- Ireland
- Prior art keywords
- radical
- compound
- formula
- methyl
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB11644/75A GB1502312A (en) | 1975-03-20 | 1975-03-20 | Quinolone derivatives |
| GB4204375 | 1975-10-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE43079L IE43079L (en) | 1976-09-20 |
| IE43079B1 true IE43079B1 (en) | 1980-12-17 |
Family
ID=26248416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE352/76A IE43079B1 (en) | 1975-03-20 | 1976-02-23 | Quinolone derivatives |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4066651A (enExample) |
| JP (1) | JPS51118773A (enExample) |
| AU (1) | AU1147676A (enExample) |
| CS (1) | CS188273B2 (enExample) |
| DD (1) | DD124117A5 (enExample) |
| DE (1) | DE2611824A1 (enExample) |
| DK (1) | DK115376A (enExample) |
| ES (1) | ES446234A1 (enExample) |
| FI (1) | FI760729A7 (enExample) |
| FR (1) | FR2304342A1 (enExample) |
| HU (1) | HU172032B (enExample) |
| IE (1) | IE43079B1 (enExample) |
| IL (1) | IL49126A0 (enExample) |
| LU (1) | LU74594A1 (enExample) |
| NL (1) | NL7602834A (enExample) |
| NO (1) | NO760993L (enExample) |
| PT (1) | PT64921B (enExample) |
| SE (1) | SE434394B (enExample) |
| SU (1) | SU648090A3 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| EP0382185B1 (en) * | 1989-02-10 | 1994-06-15 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5225402A (en) * | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| DE69128481T2 (de) * | 1990-09-07 | 1998-04-09 | Schering Corp | Antivirale und antihypertensive verbindungen |
| CA2066104C (en) * | 1991-04-19 | 2003-05-27 | Hidenori Ogawa | Benzazepine derivatives as vasopressin antagonists |
| WO1992021342A1 (en) * | 1991-06-07 | 1992-12-10 | Otsuka Pharmaceutical Co., Ltd. | Antidiabetic |
| DE19839499A1 (de) * | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
| MXPA02002032A (es) | 1999-08-27 | 2003-05-19 | Ligand Pharm Inc | Compuestos moduladores del receptor de androgeno y metodos. |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| EP1212322A2 (en) | 1999-08-27 | 2002-06-12 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| EP1216221A2 (en) | 1999-09-14 | 2002-06-26 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
| FR2811912B1 (fr) * | 2000-07-21 | 2003-02-07 | Gattefosse Ets Sa | Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees |
| AU2004266160A1 (en) * | 2003-08-22 | 2005-03-03 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| ES2409215T3 (es) * | 2007-09-14 | 2013-06-25 | Janssen Pharmaceuticals, Inc. | 4-fenil-1H-piridin-2-onas 1-3-disustituidas |
| BRPI0817101A2 (pt) | 2007-09-14 | 2017-05-09 | Addex Pharmaceuticals Sa | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas |
| SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
| ES2637794T3 (es) * | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2 |
| EP2220216A4 (en) * | 2007-11-15 | 2013-03-20 | Univ Laval | PROCESS FOR REGULATING THE PROSTAGLANDIN F-SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF |
| ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
| CA2738849C (en) | 2008-10-16 | 2016-06-28 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| ES2401691T3 (es) | 2008-11-28 | 2013-04-23 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato |
| ES2440001T3 (es) | 2009-05-12 | 2014-01-27 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| SG176018A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| US10537573B2 (en) | 2014-01-21 | 2020-01-21 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3772301A (en) * | 1971-11-22 | 1973-11-13 | Warner Lambert Co | (4-substituted)4-(methylsulfinyl)methylcarbostyrils |
-
1976
- 1976-02-23 IE IE352/76A patent/IE43079B1/en unknown
- 1976-02-25 SE SE7602339A patent/SE434394B/xx not_active IP Right Cessation
- 1976-02-27 AU AU11476/76A patent/AU1147676A/en not_active Expired
- 1976-03-01 US US05/662,685 patent/US4066651A/en not_active Expired - Lifetime
- 1976-03-01 IL IL49126A patent/IL49126A0/xx unknown
- 1976-03-17 DK DK115376A patent/DK115376A/da unknown
- 1976-03-18 FI FI760729A patent/FI760729A7/fi not_active Application Discontinuation
- 1976-03-18 DD DD191915A patent/DD124117A5/xx unknown
- 1976-03-18 NL NL7602834A patent/NL7602834A/xx not_active Application Discontinuation
- 1976-03-18 LU LU74594A patent/LU74594A1/xx unknown
- 1976-03-19 HU HU76IE00000737A patent/HU172032B/hu unknown
- 1976-03-19 NO NO760993A patent/NO760993L/no unknown
- 1976-03-19 SU SU762337250A patent/SU648090A3/ru active
- 1976-03-19 PT PT64921A patent/PT64921B/pt unknown
- 1976-03-19 DE DE19762611824 patent/DE2611824A1/de active Granted
- 1976-03-19 CS CS761804A patent/CS188273B2/cs unknown
- 1976-03-19 FR FR7608061A patent/FR2304342A1/fr active Granted
- 1976-03-20 ES ES446234A patent/ES446234A1/es not_active Expired
- 1976-03-22 JP JP51031184A patent/JPS51118773A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| SE7602339L (sv) | 1976-09-21 |
| NL7602834A (nl) | 1976-09-22 |
| SE434394B (sv) | 1984-07-23 |
| HU172032B (hu) | 1978-05-28 |
| LU74594A1 (enExample) | 1977-05-06 |
| JPS51118773A (en) | 1976-10-18 |
| CS188273B2 (en) | 1979-02-28 |
| FR2304342B1 (enExample) | 1979-09-21 |
| PT64921A (en) | 1976-04-01 |
| DD124117A5 (enExample) | 1977-02-02 |
| AU1147676A (en) | 1977-09-01 |
| DE2611824A1 (de) | 1976-09-30 |
| FI760729A7 (enExample) | 1976-09-21 |
| SU648090A3 (ru) | 1979-02-15 |
| NO760993L (enExample) | 1976-09-21 |
| JPH0122267B2 (enExample) | 1989-04-25 |
| ES446234A1 (es) | 1977-10-01 |
| FR2304342A1 (fr) | 1976-10-15 |
| IE43079L (en) | 1976-09-20 |
| US4066651A (en) | 1978-01-03 |
| DE2611824C2 (enExample) | 1987-06-19 |
| PT64921B (en) | 1977-08-24 |
| IL49126A0 (en) | 1976-05-31 |
| DK115376A (da) | 1976-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE43079B1 (en) | Quinolone derivatives | |
| US3896145A (en) | Carbazoles | |
| US3484445A (en) | Derivatives of chromone-2-carboxylic acid | |
| JP2001055377A (ja) | カンプトテシン及びカンプトテシン類似体の原料化合物の合成中間体 | |
| US3070606A (en) | Xchxn | |
| JPH04230273A (ja) | 新規カルコン化合物、その製造方法およびこれらの化合物を含有する医薬組成物 | |
| IL37749A (en) | Pyridoquinoline derivatives,their preparation and pharmaceutical compositions containing them | |
| DK149108B (da) | Analogi-fremgangsmaade til fremstilling af 5-alkoxyimidazo(1,2-a)qoinolin-2-carboxylsyrer eller estere eller kationiske salte deraf | |
| Althuis et al. | Structure-activity relationships in a series of novel 3, 4-dihydro-4-oxopyrimido [4, 5-b] quinoline-2-carboxylic acid antiallergy agents | |
| JPS634537B2 (enExample) | ||
| JPH0692371B2 (ja) | 新規複素環誘導体、その製法およびこれらを含有し、アルド−ス還元酵素抑制剤として特に有用な医薬の製法 | |
| JPH0144717B2 (enExample) | ||
| PL184860B1 (pl) | Chinoksaliny o własnościach leczniczychĆ zwłaszcza antywirusowychĆ sposób ich wytwarzania i środki lecznicze zawierające chinoksaliny jako substancje czynne | |
| Surrey et al. | The preparation of 3-halo-4-dialkylaminoalkylaminoquinoline derivatives | |
| US4138490A (en) | Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives | |
| US4390541A (en) | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease | |
| SUZUKI et al. | Synthesis of antimicrobial agents. I. Synthesis and antimicrobial activities of thiazoloquinoline derivatives | |
| NO742077L (enExample) | ||
| Elderfield et al. | Synthesis of 2-Phenyl-4-chloroquinolines1 | |
| Pan et al. | Derivatives of fluorene. IX. 4-Hydroxy-2-Fluorenamine; new 3, 4-benzocoumarin Derivatives1 | |
| US4187310A (en) | 1,2-Dihydro-2-oxoquinol-4-ylacetic acid derivatives and pharmaceutical compositions | |
| EP0008610B1 (en) | Furonaphthyridine compounds, process for their preparation and pharmaceutical compositions containing them | |
| Martin-Smith et al. | Benzothiophene-4, 5-quinones | |
| Bailey et al. | 282. Synthetical experiments in the chelidonine–sanguinarine group of the alkaloids. Part II | |
| Lee | Synthesis of the mangostins |